MTOR and hepatocellular carcinoma: The results indicated that in the presence of lenvatinib, overexpression of circRNA‐mTOR significantly enhanced the sphere‐forming ability of HCC cells, whereas curtailing circRNA‐mTOR expression significantly reduced the sphere‐forming ability of HCC cells (Figure 4E; Figure S2E, Supporting Information).